By Mary de Wet


Lineage Cell Therapeutics Inc. shares rose 12% to $2.37 in premarket trade Monday after the company said it has a collaboration and license agreement with Roche and Genentech, a member of the Roche Group, to develop and commercialize a retinal pigment epithelium cell therapy to treat eye disorders.

Genentech will assume responsibility for further clinical development and commercialization of Lineage's OpRegen program, which is being evaluated in a Phase 1/2a dose escalation safety and efficacy study in patients with advanced dry age-related macular degeneration with geographic atrophy.

Under the terms of the agreement, Lineage will complete activities related to the clinical study and perform certain manufacturing activities. Genentech will pay Lineage a $50 million upfront payment and Lineage is eligible to receive up to $620 million in additional development, approval and sales milestone payments, in addition to tiered double- digit royalties.


Write to Mary de Wet at


(END) Dow Jones Newswires

December 20, 2021 06:36 ET (11:36 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Historical Stock Chart
From Jun 2022 to Jul 2022 Click Here for more Roche (QX) Charts.
Historical Stock Chart
From Jul 2021 to Jul 2022 Click Here for more Roche (QX) Charts.